Petauri™ Acquires Formulary Insights™ in Market Access Expansion
Rapidly growing pharmaceutical services platform bolsters pricing and market access offering, merging business with Petauri Advisors
With the acquisition and merger, Petauri rapidly expands its capabilities in serving the pharmaceutical industry by leveraging Formulary Insights' industry-leading market access research platforms. This integration will enable Petauri Advisors to provide a full suite of consulting services, including enhanced market access strategy, accelerated business development and licensing (BD&L) due diligence evaluations, and the facilitation of access-informed decision-making for clients.
"Since 2021, Formulary Insights has developed actionable market access insights and strategies for over 40 biopharmaceutical manufacturers," said
"Combining Formulary Insights' market access insights and strategic capabilities with Petauri Advisors' established consulting practice represents a significant step forward in our mission to deliver transformative payer and health system approaches to pharmaceutical and life sciences clients," said
About Petauri
Petauri is a purpose-built pharmaceutical services platform based in
Media Contact:
Glue Advertising and Public Relations
[email protected]
718-404-9277
View original content to download multimedia:https://www.prnewswire.com/news-releases/petauri-acquires-formulary-insights-in-market-access-expansion-302303465.html
SOURCE Petauri
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 20 Years On, Qinghai-Xizang Railway Continues to Reshape the Region
- Sunny Hostin Signs with Fountain 0 to License Her Image for Appearances in Upcoming Films Which She Looks to Produce Based on Her Best-Selling Books
- Professional Paper Tube Manufacturer Sprintpackage Expands to 20,000 SQM Facility
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share